These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26655262)

  • 1. Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.
    Pillai AM; Knapp FF
    Curr Radiopharm; 2016; 9(1):6-7. PubMed ID: 26655262
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177.
    Demirkol MO; Kiremit MC; Acar O; Falay O; Ucar B; Esen T
    Clin Genitourin Cancer; 2018 Apr; 16(2):99-102. PubMed ID: 29074285
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Ferdinandus J; Violet J; Sandhu S; Hofman MS
    Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
    J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
    [No Abstract]   [Full Text] [Related]  

  • 6. Multidose formulation of ready-to-use
    Chakraborty S; Vimalnath KV; Chakravarty R; Sarma HD; Dash A
    Appl Radiat Isot; 2018 Sep; 139():91-97. PubMed ID: 29734118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.
    Sachpekidis C; Alberts I; Rominger A; Afshar-Oromieh A
    Immunotherapy; 2019 Oct; 11(15):1267-1271. PubMed ID: 31496329
    [No Abstract]   [Full Text] [Related]  

  • 8. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.
    Kratochwil C; Giesel FL; Eder M; Afshar-Oromieh A; Benešová M; Mier W; Kopka K; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):987-8. PubMed ID: 25573634
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
    Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
    J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutetium
    Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
    J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-targeted therapy in prostate cancer.
    Tagawa ST
    Clin Adv Hematol Oncol; 2021 Feb; 19(2):74-77. PubMed ID: 33596187
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of the radiation absorbed dose produced by
    Azorín-Vega E; Rojas-Calderón E; Ferro-Flores G; Aranda-Lara L; Jiménez-Mancilla N; Nava-Cabrera MA
    Appl Radiat Isot; 2019 Apr; 146():66-71. PubMed ID: 30753987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSMA-targeted radioligand therapy in prostate cancer].
    Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
    Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.
    Calopedos RJS; Chalasani V; Asher R; Emmett L; Woo HH
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):352-360. PubMed ID: 28440324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EANM procedure guidelines for radionuclide therapy with
    Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses.
    Al-Rashdan R; Al-Abdallat H; Sathekge MM; Mirzaei S; Shahait M; Al-Khawaldeh K; Abdlkadir AS; Lee S; Al-Ibraheem A
    Nuklearmedizin; 2024 Jun; 63(3):188-198. PubMed ID: 38262473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
    Ahmadzadehfar H; Essler M
    J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
    Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P
    In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
    Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
    Molecules; 2020 May; 25(11):. PubMed ID: 32486054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.